Hidradenitis Suppurativa
Conditions
Brief summary
Percentage change from baseline in abscess and inflammatory nodule (AN) count at Week 16
Detailed description
Achieving HiSCR50 at Week 16; Achieving HiSCR75 at Week 16, Absolute change from baseline in Dermatology Life Quality Index (DLQI) score at Week 16; Absolute change from baseline in Patient's Global Assessment of Hidradenitis Suppurativa (HS-PtGA) score at Week 16; Absolute change from baseline in skin pain numerical rating scale (NRS) at Week 16, Incidence and severity of treatment emergent adverse events (TEAEs); Absolute change from baseline in vital signs, electrocardiogram (ECG) parameters, and clinical laboratory results
Interventions
DRUGTibulizumab
Sponsors
Zura Bio Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage change from baseline in abscess and inflammatory nodule (AN) count at Week 16 | — |
Secondary
| Measure | Time frame |
|---|---|
| Achieving HiSCR50 at Week 16; Achieving HiSCR75 at Week 16, Absolute change from baseline in Dermatology Life Quality Index (DLQI) score at Week 16; Absolute change from baseline in Patient's Global Assessment of Hidradenitis Suppurativa (HS-PtGA) score at Week 16; Absolute change from baseline in skin pain numerical rating scale (NRS) at Week 16, Incidence and severity of treatment emergent adverse events (TEAEs); Absolute change from baseline in vital signs, electrocardiogram (ECG) parameters, and clinical laboratory results | — |
Countries
Germany, Hungary, Poland, Spain
Outcome results
None listed